Senior onderzoeker Infectieziekten in de Eerste Lijn, surveillance
Publicatie
Publicatie datum
Rotavirus.
de Oliveira Bressane Lima, P., Verberk, J.D.M., Suijkerbuijk, A.W.M., Pijnacker, R., Veldhuijzen, I.K., Mollers, M., Dongen, J.A.P. van, Vennema, H., Hooiveld, M., Bruijning-Verhagen, P., Melker, H.E. de. Rotavirus. In: Schurink-van 't Klooster and H.E. de Melker (Eds.)The National Immunisation Programme
in the Netherlands: Surveillance and developments in 2018-2019. RIVM, Bilthoven p. 212-218.
Download de PDF
Key points
- The rotavirus season in 2018 was comparable to that in 2017, contradicting the previous hypothesis of a biennial pattern that was formulated due to low-endemic rotavirus seasons in 2014 and 2016. Until mid-July 2019, fewer rotavirus cases have been observed compared to the same period in 2018.
- In July 2018, the Ministry of Health, Welfare and Sport decided to offer vaccination to infants belonging to risk groups. The process of implementation is ongoing.
- G9P8 and G3P8 were the most prevalent genotypes in 2018.
- A thermostable vaccine (ROTASIIL) has achieved WHO prequalification. Four rotavirus vaccines are currently available worldwide, of which two (Rotarix and RotaTeq) are licensed for use in Europe.
- The rotavirus season in 2018 was comparable to that in 2017, contradicting the previous hypothesis of a biennial pattern that was formulated due to low-endemic rotavirus seasons in 2014 and 2016. Until mid-July 2019, fewer rotavirus cases have been observed compared to the same period in 2018.
- In July 2018, the Ministry of Health, Welfare and Sport decided to offer vaccination to infants belonging to risk groups. The process of implementation is ongoing.
- G9P8 and G3P8 were the most prevalent genotypes in 2018.
- A thermostable vaccine (ROTASIIL) has achieved WHO prequalification. Four rotavirus vaccines are currently available worldwide, of which two (Rotarix and RotaTeq) are licensed for use in Europe.